Jazz Pharmaceuticals (NASDAQ:JAZZ) Given New $155.00 Price Target at Royal Bank Of Canada

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its target price lifted by Royal Bank Of Canada from $151.00 to $155.00 in a research note issued to investors on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the specialty pharmaceutical company’s stock.

Several other analysts also recently weighed in on the company. Wells Fargo & Company set a $170.00 target price on Jazz Pharmaceuticals in a research note on Wednesday, October 22nd. Morgan Stanley set a $183.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, October 24th. JPMorgan Chase & Co. dropped their target price on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. The Goldman Sachs Group increased their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Finally, Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $178.50.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded down $2.89 on Thursday, reaching $131.16. The stock had a trading volume of 1,041,733 shares, compared to its average volume of 893,234. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The business’s 50-day moving average price is $133.21 and its two-hundred day moving average price is $119.30. The stock has a market cap of $7.96 billion, a P/E ratio of -19.49, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 EPS for the quarter, topping the consensus estimate of $5.87 by $2.26. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.11 billion. During the same quarter last year, the firm posted $6.54 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, sell-side analysts forecast that Jazz Pharmaceuticals will post 16.96 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the sale, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. LSV Asset Management lifted its position in shares of Jazz Pharmaceuticals by 3.6% during the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after buying an additional 87,576 shares during the period. Dimensional Fund Advisors LP raised its stake in Jazz Pharmaceuticals by 14.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company’s stock worth $289,066,000 after acquiring an additional 293,360 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after acquiring an additional 191,637 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Jazz Pharmaceuticals by 8.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after purchasing an additional 145,865 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 41.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after purchasing an additional 391,660 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.